Edgewise Therapeutics, Inc. (EWTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$43.07+2.67%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — EPS remains positive in 2026 with improvement from prior losses: Q2 EPS -0.53 USD vs FY target 1.28 USD.
Edgewise Therapeutics is advancing its CIRRUS-HCM Part D data reporting on time by Q2 2026. The company recently made a positive asset purchase agreement with Servier Pharmaceuticals. Earnings have shown improvement with recent beats. The stock price has risen over 15% in the last month, reflecting growing investor interest.
Edgewise remains loss-making with uncertain revenue growth beyond 2026. The company missed earnings in early 2026 and faces execution risks on its new agreement. Analysts expect EPS to decline in 2027, signaling challenges ahead.
The market price is about 16% below our valuation level and aligns with the median analyst price consensus. The market expects some challenges with a negative implied growth rate over 3 to 5 years. Our view differs by focusing on the potential from the asset purchase and data reporting milestones.
Breaks if: Data report delayed beyond Q2 2026
Breaks if: EPS falls below 1.28 USD in FY 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but has stable management and is focused on advancing its clinical programs, which could lead to future growth.
The market appears to have low expectations for EWTX, as indicated by its current valuation. There is a fragility tier of low, suggesting that the stock is not overly sensitive to negative news at this time.
Fundamentals are likely to remain weak in the near term, given the company's recent earnings miss and the overall performance of its industry peers. However, management is on track with key priorities, which may support future improvements.
The long-term thesis hinges on management's ability to execute on its clinical programs and the overall health of the healthcare sector. Key triggers include guidance updates and performance from sector bellwethers.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the thesis. The company reported a Q2 EPS of -0.53, missing the consensus estimate of -0.48. This performance continues to sit well below its industry cohort.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Failure to execute or integrate asset purchase by end 2026
Edgewise Therapeutics announced an Asset Purchase Agreement with Servier Pharmaceuticals on May 31, 2026.
Over the next 1 to 3 years, EWTX's performance will depend on its clinical advancements and sector dynamics. Not investment advice.